Company Overview of OvaScience, Inc.
OvaScience, Inc., a life sciences company, is engaged in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries. It is developing various fertility treatment options designed to enhance egg quality and in vitro fertilization (IVF) comprising AUGMENT to improve egg quality and increase the success of IVF by transferring mitochondria from a woman's EggPCs to her mature egg during IVF; OvaPrime for boosting a woman's egg reserve by transferring the EggPCs from the outer layer of her ovary back into the ovary prior to IVF; OvaTure to create mat...
215 First Street
Cambridge, MA 02142
Founded in 2011
Key Executives for OvaScience, Inc.
Total Annual Compensation: $106.3K
Compensation as of Fiscal Year 2013.
OvaScience, Inc. Key Developments
OvaScience, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:30 PM
Jan 8 15
OvaScience, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Michelle Dipp, Co-Founder, Chief Executive Officer and Director.
OvaScience, Inc. Announces Resignation of Stephen Kraus from Board of Directors and the Compensation Committee and the Nominating and Corporate Governance Committee
Dec 24 14
On December 23, 2014, Stephen Kraus resigned from the OvaScience, Inc. Board of Directors and the Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. His resignation was not the result of a disagreement on any matter related to the company's operations, policies or practices.
OvaScience, Inc. Announces Executive Changes
Dec 11 14
OvaScience, Inc. promoted chief scientific officer Arthur Tzianabos to president, succeeding Michelle Dipp, who will continue to serve as CEO under an extended employment contract. The company also appointed David Harding as chief commercial officer. Previously, Harding held various positions at Hologic Inc. (HOLX), most recently as senior vice president and general manager of the company's women's health division.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|